Still, understanding the interplay of aSyn, Aβ, and tau pathology in PD and DLB is of interest as it will inform the interpretation of AD biomarkers in these populations as these assays become more widely available and stratifying clinical trials by the presence or absence of AD co-pathology may be of interest [201]. This evidence concerns the gene MAPT and Alzheimer disease.